Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
1. Genmab's Tivdak approved for recurrent cervical cancer in Japan. 2. Tivdak shows significant survival benefits over chemotherapy in trials. 3. Approval based on Phase 3 innovaTV 301 trial data. 4. Genmab leads commercialization of Tivdak in Japan and other regions. 5. GMAB stock rose 3.06% following the announcement.